Other substances

Candesartan

An angiotensin II receptor blocker.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Candesartan is a benzimidazole derivative used for hypertension treatment (ChEBI).

Candesartan on DrugBank
Candesartan on PubChem
Candesartan on Wikipedia

CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease 3CLpro Small molecule In vitro In silico	in silico; Vero E6 cells		Showed low free energy in a molecular docking in silico analysis with SARS-CoV-2 3C-like protease (high affinity) and sufficient stability within molecular dynamics simulation of the interaction. Candesartan prodrug (Candesartan Cilexetil) displayed anti-SARS-CoV-2 activity in Vero E6 cells with a relatively high selectivity index (45.1).	Dec/03/2020

AI-suggested references

Link	Publication date
ACE2 as a potential therapeutic target for pandemic COVID-19	Nov/01/2020
Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study.	May/24/2021
Candesartan could ameliorate the COVID-19 cytokine storm.	Aug/20/2020
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays	May/05/2021
Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers-Relevance to COVID-19.	Jul/03/2021
Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study	Nov/08/2021
Discovery of Small-Molecule Inhibitors of SARS-CoV-2 Proteins Using a Computational and Experimental Pipeline.	Jul/09/2021
Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease	Jun/29/2020

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04351724	Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)	Recruiting	Phase 2\|Phase 3	Apr/16/2020	Mar/31/2022
Alternative id - ACOVACT Interventions - Drug: Chloroquine or Hydroxychloroquine\|Drug: Lopinavir/Ritonavir\|Other: Best standard of care\|Drug: Rivaroxaban\|Drug: Thromboprophylaxis\|Drug: Candesartan\|Drug: non-RAS blocking antihypertensives\|Drug: Remdesivir\|Drug: Asunercept 400mg\|Drug: Asunercept 100mg\|Drug: Asunercept 25mg\|Drug: Pentaglobin Study type - Interventional Study results - No Results Available Locations - Medical University of Innsbruck, Innsbruck, Tirol, Austria\|Medical University of Graz, Graz, Austria\|Kepler University Hospital, Linz, Austria\|Medical University of Vienna, Vienna, Austria\|Wilhelminenspital, Vienna, Austria\|SMZ Süd Kaiser Franz Josef Spital, Vienna, Austria\|KH Hietzing, Vienna, Austria\|SMZ Baumgartner Höhe Otto Wagner Spital, Vienna, Austria\|SMZ Ost Donauspital, Vienna, Austria Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 500 Age - 18 Years to 99 Years (Adult, Older Adult) Outcome measures - sustained improvement (>48h) of one point on the WHO Scale\|Time to improvement on WHO Scale\|Mean change in the ranking on an ordinal scale from baseline\|time to discharge or a National Early Warning Score (NEWS) ≤2 (maintained for 24h), whichever occurs first\|change from baseline in National Early Warning Score (NEWS)\|Oxygenation free days\|Incidence of new oxygen use during the trial\|duration of oxygen use during the trial\|Ventilator free days until day 29\|Incidence of new mechanical ventilation use during the trial\|duration of mechanical ventilation use during the trial\|Viral load/viral clearance\|Duration of Hospitalization\|Mortality\|Obesity - mortality\|Obesity - duration of hospitalization\|Obesity - ICU admission\|Obesity - new oxygen use\|Drug-drug interactions with lopinavir/ritonavir\|Renin Angiotensin System (RAS) fingerprint\|SpO2/FiO2 ratio\|paO/FiO2 ratio\|modified Sequential Organ Failure Assessment\|C-reactive protein\|Interleukin-6\|procalcitonin\|IgM Concentrations\|IgA Concentrations\|differential blood counts
NCT05122182	Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19	Not yet recruiting	Phase 2	Dec/08/2021	Dec/29/2022
Alternative id - CTC0312 Interventions - Drug: Candesartan Cilexetil\|Drug: Repagermanium\|Drug: Candesartan Placebo\|Drug: Repagermanium Placebo Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 600 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Clinical Health Score at day 14\|Clinical Health Score at day 28\|ICU admission\|Death\|Time to death\|Acute Kidney Injury\|Respiratory Failure\|Length of hospital admission\|Length of ICU Admission\|Requirement of ventilatory support\|Requirement of dialysis\|Clinical Health Score at day 60\|Clinical Health Score at day 90\|Clinical Health Score at day 180

Export (.csv)